Liver Cancer News
Click on the title to read the rest of the Liver Cancer News story.
Aflatoxins: A Cause Of Hepatocellular Carcinoma
30 April 2019
The most common cause of Hepatocellular Carcinoma are aflatoxins. Aflatoxins are the byproducts of fungi that are found on agricultural crops like maize, peanut, cottonseed and tree nuts. There are more than 14 types of aflatoxins but AFB1, B2, G1, G2 are more common and carcinogenic to human and animals. When aflatoxin amounts increase, and when is a continuous exposure, this will cause AFBO to bind to the proteins and cause necrosis of the hepatocytes which can lead to cirrhosis. AFBO binds to DNA, which leads to genetic change in the target cell and causes DNA strand breakage. DNA base damage and oxidative damage ultimately leads to cancer.
Deals And Data In The Offing For Oncimmune
25 April 2019
The London-listed diagnostics group Oncimmune, is focusing on growing sales, and is looking forward to publishing trial data soon. They are looking to use the immune system to diagnose cancer. Oncimmune sells EarlyCDT-Liver to detect Hepatocellular Carcinoma and has tests for many other cancers as well. Their current trial data involves the EarlyCDT-Lung cancer test. Oncimmune has an agreement with Genostics, in which Genostics has licensed the entire EarlyCDT portfolio.
Most Patients Stick With Milciclib In Tiziana Life Sciences Study
24 April 2019
The biotechnology firm, Tiziana Life Sciences PLC, has reposted data from its clinical trial involving milciclib in patients with advanced liver cancer. 80% of patients who completed treatment within the phase 2a trial have requested continuation of the treatment. A safety review stated, the treatment “was not associated with unexpected signs or signals of toxicity” when administered to patients with advanced Hepatocellular Carcinoma. Ten patients were administered Milciclib over a six-month study period. “Demonstration of safety and clinical activity is important milestone to move forward with strategic options for further clinical development of milciclib either as a single agent or in combination with one of the [US Food & Drug Administration] approved drugs for treatment of [Hepatocellular Carcinoma] patients,” said Tiziana Chief Executive & Chief Scientific Officer Kunwar Shailubhai.
Using Yttrium-90 For Liver Cancer Therapy In Clinical Stage
24 April 2019
Radioembolization (Y90) is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed a tumor. Pars Isotop Company is the main producer of the new radiopharmaceutical. Y-90 resin microspheres has been tested on 12 patients with liver cancer, with the help of Tehran and Shiraz Medical Sciences Universities. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs which have radioactivity.
Urine-Based Liquid Biopsy For Non-Urological Cancers
23 April 2019
Advances in technology and science, now use less invasive blood liquid biopsy for the study of cancer genetics. Early research was limited to tissue specimens obtained from invasive biopsy and surgical resections. Molecular biomarker research and show that tumor-derived DNA in the circulation can be detected in urine. Using Hepatocellular Carcinoma (HCC) as a study model, scientists further demonstrated the detection of ctDNA in the urine. The data results show that the HMW urine DNA was mostly derived from the sloughed-off cell debris of the urinary tract, and the LMW urine DNA was mostly derived from the circulation that was enriched for tumor-derived DNA alterations if a tumor was present.
What’s The Most Cost-Effective Imaging Method For Diagnosing, Monitoring HCC Patients?
22 April 2019
According to a study published in the American Journal of Roentgenology. CT diagnosis and surveillance of Hepatocellular Carcinoma (HCC) is the most cost-effective imaging-based strategy. North American guidelines currently recommend ultrasound (US) surveillance every six months in patients at risk for HCC. According to Lima et al., strategies that rely solely on a single exam for surveillance and diagnosis, such as strategy E, are more likely to have higher rates of false-positive diagnoses. “Before implementing a surveillance program incorporating imaging modalities other than ultrasound, future studies should address the economic burden associated with false-positive HCC diagnoses. Also, future prospective trials should assess the accuracy of abbreviated MRI examinations in a surveillance setting,” the authors concluded.
Research Closer To Finding Ways To Help Patients With Hepatitis
20 April 2019
MicroRNA are small, single-stranded non-coding RNAs that regulate T-cell immunity by targeting key factors, signaling and proteins and cytokines associated with T-cell activation, differentiation, and function. T-cell immunity plays a vital role in pathogen infections. Although the host innate immune system senses and responds to eliminate it, the hepatitis C virus evades the onslaught and establishes persistent infection in the liver. The immune system has developed two areas, innate and adaptive immunity. They work together to prevent infection and limit the damage done by invading bugs. While, liver resection remains the popular treatment for Hepatocellular Carcinoma (HCC), the aim of this study was to explore alterations of immune cells in HCC patients with liver resections. Regulatory T-cells are shown to increase the peripheral blood in HCC.
100 Patients From Odisha Undergo Liver Transplant At Gleneagles Global Hospital Hyderabad
20 April 2019
Lakdi-ka-pul is currently host to one of the busiest and comprehensive liver disease management programs. The center performs adult as well as pediatric liver transplants. So far, they have performed over 700 liver transplants which includes over 100 pediatric liver transplants. The hospital has exclusive liver (Intensive Care Unit) ICU and liver (Occupational Therapy) OT. The visionary leader and well acclaimed surgeon and Chairman of Gleneagles Global Hospitals, Dr. K. Ravindranath dreamt to set up world-class multi organ transplant centers in India and collaborated with Kings College hospital in London. “If any of the liver tests are abnormal, then they definitely indicate the need for additional evaluation” he stated.
AGA Clinical Practice Update: DAAs For Hepatitis C And Hepatocellular Cancer
19 April 2019
The American Gastroenterological Association collected evidence describing interactions between oral direct-acting antiviral (DAA) therapy for hepatitis C and hepatocellular cancer regarding incidence, recurrence, and efficacy. DAA treatments are associated with reduced incidence of hepatocellular cancer and relative reduction is similar for patients with and without cirrhosis. For patients with cirrhosis, achieving sustained virologic response, hepatocellular cancer incidence and hepatocellular cancer survival was similar between DAA-treated patients and interferon-treated patients. Conflicting studies fail to show conclusive data that DAA therapy is associated with differential time-to-recurrence, decreased or increased risk, or recurrent hepatocellular cancer aggressiveness in patients who achieve complete response to hepatocellular cancer therapy. DAA therapy should not be withheld from these patients, but DAA therapy can be deferred for 4 to 6 months to confirm therapy response Patients will also require indefinite surveillance every 3 to 6 months with dynamic contrast enhanced computerized tomography or magnetic resonance imaging.
Liquid Biopsy: An Old Concept With A New Twist
18 April 2019
A liquid biopsy is a simple noninvasive alternative to tissue biopsies, in which a body fluid specimen is obtained for detailed laboratory analyses. A liquid biopsy for cancer detection or management is an old concept with a new twist. Tumor cells were first found in circulation in the late 19th century, and the term “cell-free DNA (cfDNA),” which referred to fragmented DNA found outside cells in the blood, was first reported by Mandel and Metais in 1948. Then, work in the 1970s revealed that patients with cancer tended to have an increased concentration of cfDNA in their blood. A study by Cohen and his team of scientists used a test called CancerSEEK that showed promise for cancer screening by liquid biopsies. Their cohort involved more than 1000 patients with cancer. Their findings suggested that individuals who test positive twice by liquid biopsy should undergo imaging to find the tumor site.
Real-Life Experiences Demonstrate Benefit Of Sorafenib-Regorafenib Sequential Therapy In Advanced HCC
18 April 2019
Patients with advanced Hepatocellular Carcinoma (HCC) demonstrated real-life benefit in a study with sorafenib (Nexavar) followed by regorafenib (Stivarga). Overall survival (OS) benefit with the sequence of targeted therapies was significant when calculated from the initiation of first-line treatment. Findings from the phase III RESORCE trial led to the approval in April 2017 of regorafenib as a second-line therapy for patients with unresectable HCC who had previously received treatment with sorafenib. Patients with HCC who received regorafenib after progression on sorafenib treatment demonstrated a median OS of 10.6 months.
Celsion Corporation Announces Issuance Of New Patent For Thermodox®
17 April 2019
Celsion Corporation, a clinical stage oncology drug development company, announced that the United States Patent and Trademark Office has granted U.S. Patent No. 10,251,901 B2 – Thermosensitive Nanoparticle Formulations and Method of Making the Same. This new patent strengthens the coverage of ThermoDox®, Celsion’s heat-activated liposomal platform technology, currently in Phase III development for the treatment of primary liver cancer. The Company’s 556-patient global Phase III OPTIMA Study in HCC completed enrollment in August 2018 at 65 clinical sites in North America, Europe, China, S. Korea, Taiwan and Southeast Asia.
New Role For Innate Immune Sensor: Suppressing Liver Cancer
16 April 2019
UT Southwestern researchers have found that a protein in the body’s innate immune system that responds to gut microbes can suppress the most common type of liver cancer. They have shown that NLRP12, an innate immune sensor, has a protective effect against Hepatocellular Carcinoma (HCC). In this study, we demonstrated that NLRP12 responds to gut microbes and plays a critical role in suppressing a common form of liver cancer,” said Dr. Hasan Zaki, Assistant Professor of Pathology at UT Southwestern and corresponding author of the study. To understand why this occurred, the researchers looked at the signals sent by tumor cells in mice with and without the NLRP12 gene. Dr. Zaki said his team is now further exploring the precise mechanism through which NLRP12 regulates the JNK pathway.
Some Patients May Be Eligible For Liver Resection After SIRT
16 April 2019
Researchers have reported that patients that have undergone selective internal radiotherapy (SIRT) with yttrium-90 (Y-90) may be eligible for liver resection. To better understand the circumstances in which resection is possible, the investigators reviewed data on all patients who underwent liver resection following SIRT. There were 12 patients who were treated with SIRT followed by liver resection, 5 of which had HCC. According to RECIST (response evaluation criteria in solid tumors), there was a partial response shown in all cases. “In selected cases, liver resection is possible post SIRT. As this can represent a potentially curative option, it is important to reconsider resection in the follow-up of patients undergoing SIRT,” the researchers said.
Cancer ‘Vaccine Factories,’ Cataloguing DNA Weaknesses, NHS Drug Decisions And Cancer Sniffing Canines
13 April 2019
Scientists from the Wellcome Sanger Institute in Cambridge are building a list of the most promising potential cancer drug targets. The team is using the DNA-editing tool CRISPR to switch off every gene, one-by-one, in over 300 different types of lab-grown cancer cells. So far, they’ve ranked 600 promising drug targets. Immune-boosting combo could help create cancer ‘vaccine factories.’ Scientists in the US are investigating the potential benefits of a highly purified version of the chilli compound capsaicin in slowing cancer spread. A trio of beagles were trained to ‘sniff out cancer.’ The dogs were able to pick out patients with lung cancer that had spread to other parts of the body with a 96.7% accuracy.
FDA Approves Expanded Monotherapy Label For Merck’s KEYTRUDA® (pembrolizumab)
12 April 2019
In the Phase 3 KEYNOTE-042 trial KEYTRUDA monotherapy demonstrated a statistically significant improvement in OS compared with chemotherapy alone in patients. The study was a randomized, multi-center, open-label, active-controlled and enrolled 1,274 patients. KEYTRUDA is indicated for the treatment of patients with Hepatocellular Carcinoma (HCC) who have been previously treated with sorafenib. The recommended dose of KEYTRUDA is 200 mg as an intravenous infusion over 30 minutes every three weeks up to 24 months.
New Cancer Vaccine Study Has Similarities To U Of R Research
12 April 2019
New York Mount Sinai Hospital tested the new vaccine on 11 patients who have advanced stage lymphoma and has shown to be successful. The vaccine is used in people who already have cancer. Immune stimulants are injected directly into a tumor to teach the immune system to destroy it. Some patients had full remission from months to years. The study was published earlier this month in Nature Medicine. “This is very different from a preventative vaccine,” said Dr. Patrick Reagan, assistant professor of medicine at URMC. “This is a vaccine where we are actually trying to stimulate your immune system to attack the cancer.” The vaccine is also being tested in the lab for liver cancer.
Ledipasvir/Sofosbuvir ± Ribavirin Effective, Safe In HCV With Advanced Liver Disease
11 April 2019
A recent study involving multiple centers found that Ledipasvir and Sofosbuvir with or without Ribavirin is an effective and tolerable treatment in patients with hepatitis C virus (HCV)-infection with advanced liver disease. The study involved 200 patients with chronic hepatitis C with advanced liver disease to determine the association of ledipasvir and sofosbuvir treatment with a new occurrence and/or recurrence of HCC during and after antiviral treatment. HCC recurrence was less common in patients who received curative treatment for HCC compared with those who received noncurative treatment.
Can-Fite Announces Late-Breaking Abstract Presentation On Namodenoson™ Phase II Results At ASCO
10 April 2019
Can-Fite BioPharma Ltd., a biotechnology company, just completed a multicenter Phase II trial in patients with advanced liver cancer. The trial was a randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102). Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers as well.
Discovery Of A Host mRNA That Inhibits Immune Functions Of Antiviral Protein RIG-I
10 April 2019
A group of scientists at Kanazawa University investigated the effects of SeP on antiviral immune responses in the liver, using cultured cells, mice and clinical specimens. They found that HCV infection augmented SeP expression in cultured cells. By analyzing clinical specimens, it was found that serum SeP levels were higher in HCV-infected patients. RIG-I protein was thought only to recognize RNAs of pathogens invading cells thus protecting against pathogens. So far, very few host mRNAs have been reported acting like SeP mRNA, which functions as a ‘decoy’ to bind RIG-I thus repressing its functions. This information is important for understanding immune tolerance in the liver and autoimmune diseases. The study is expected to lead to further investigations of host RNAs regulating RIG-I and to the development of clinical application targeting such mRNAs.
The Protein P38gamma Identified As A New Therapeutic Target In Liver Cancer
10 April 2019
A recent research study conducted by a team of researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) led by Guadalupe Sabio has discovered an enzyme that could become a new pharmacological target in the treatment of liver cancer. They have shown an important role for p38gamma in the initiation of cell division in the liver, and that p38gamma and CDK2 both act as a tumor suppressor. To test whether p38gamma is implicated in cell division, study first author Antonia Tomás-Loba examined the outcome of chemically inducing liver cancer in mice that lack the enzyme. Her results were very promising.
Peripheral Neuropathy Reported In Liver Cancer Drug Stivarga
9 April 2019
The Ministry of Food and Drug Safety plans to review the European Commission’s safety information about Stivarga (regorafenib). A patient reported peripheral neuropathy while taking Stivarga. Peripheral neuropathy causes infections in peripheral nerves at the tips of fingers and toes and makes them feel numb. In severe cases, patients find it difficult to walk, and experience a poor sense of balance. Result from the RESORCE trial on 573 patients in 21 countries showed the median overall survival of patients who used Stivarga after Nexavar treatment was 26 months. Stivarga was developed by Bayer as a potent in liver cancer treatment.
Personalized T Cells Destroy Common Liver Cancer
9 April 2019
Researchers have engineered hepatitis B virus-specific T cells, a type of immune cell found in the body, to treat Hepatocellular Carcinoma. The t-cells were then individualized to the patient. The team successfully performed the approach on two liver transplanted patients who had hepatitis B virus (HBV) associated liver cancer recurrence. “In this study we showed that the integrated HBV-DNA gene components in the HCC cells were able to activate functional HBV-specific T cells,” says senior coauthor Antonio Bertoletti, a professor from the emerging infectious diseases program at Duke-NUS Medical School. The researchers plan to further refine the technique and treatment strategy with further research and trials to improve the efficacy of the therapy.
Blue Faery Grants Liver Cancer Research Award
8 April 2019
This year Blue Faery: The Adrienne Wilson Liver Cancer Association announced their winner of the Blue Faery Award (BFA) for Excellence in Liver Cancer Research was given to Dr. Jinsil Seong, Professor at Yonsei University Medical College. Professor Seong is one of a few who pioneered radiotherapy of Hepatocellular Carcinoma. She has devoted her entire career on radiotherapy of HCC by practicing, educating and pursuing clinical research. Upon receiving the BFA Dr. Jinsil Seong stated, “I am truly honored and impressed to join world leaders in [the] HCC field who won the award previously. This encourages me to keep going forward for [a] better future of our HCC patients!” She is currently the president-elect of the Asia Pacific Primary Liver cancer Expert (APPLE) association, which is a world leading liver cancer association.
U.S. Liver Cancer Deaths More Common With Less Education
8 April 2019
In a recent observational study, researchers collected data from the year 2000 through 2015. They found that nationwide, liver cancer death rates rose from 7.5 to 11.2 fatalities for every 100,000 men, and from 2.8 to 3.8 fatalities for every 100,000 women. These patients were between 25 and 74 years old. In men, however, the increases only occurred among those without a college degree. Among women, liver cancer death rates rose across all education levels, with the smallest increase for college-educated women. Risk of dying from liver cancer can mitigated if a person has a better job, better insurance, or a healthier lifestyle.
TGen Finds Gene Associated With Most Common Liver Cancer
7 April 2019
Dr. Johanna DiStefano, head of the Diabetes and Fibrotic Disease Unit at Translational Genomics Research Institute (TGen) and researchers provide experimental evidence supporting the AKR1B10 enzyme as a promising therapeutic target for HCC. This gene was first identified and characterized in 1998. AKR1B10 has a conflicting role in HCC development and progression. An over-expression may indicate a patient has HCC, and the suppression of this gene may also be a way to stop cancer progression. AKR1B10 has emerged as a potential biomarker for the diagnosis and prognosis of HCC, studies show this enzyme also plays a role in the development and progression of HCC.
Hormone That Protects Women From Liver Cancer
6 April 2019
Guadalupe Sabio at the Spanish National Center for Cardiovascular Research (CNIC) in Spain and staff have have discovered that a hormone that if present at higher levels in women, can keep them away from liver cancer. Their study also suggests that the disease is more common in men. Using mouse models, they found that inhibiting testosterone production in males, increased their adiponectin levels and reduced tumor growth. Most importantly, their study showed that adiponectin and metformin, a common antidiabetic drug, could be used as novel treatments for liver cancer.
After A Delay, Can-Fite Digs Into Subpopulation Data As Liver Cancer Drug Fails To Hit Primary Endpoint
26 March 2019
Israeli biotech Can-Fite missed the primary endpoint in a mid-stage test of its experimental late-stage liver cancer drug namodenoson. The study failed to achieve a boost in median overall survival across 78 patients with varying forms of advanced liver cancer. The A3 adenosine receptor agonist was originated by researchers at the National Institutes of Health. Last summer, Can-Fite delayed publication of the data from this trial, saying at the time that the delay was due to “the unexpected longevity of patients enrolled into this trial,” according to its medical director, Michael Silverman, M.D.
Whole Grains Help Reduce Liver Cancer By 40 Percent
22 March 2019
Preliminary research advises that a diet containing whole grains may reduce the risk of liver cancer by 40 percent. Liver cancer, particularly Hepatocellular Carcinoma or HCC, is projected to become the third most common type of cancer by 2030. The study looked at over 125,000 patients and found that an increase of whole grains is related to a reduced risk of liver cancer. Those who consumed the highest amounts of whole grains had a 37 percent lower risk of liver cancer compared to those who consumed the least amount. The study showed that a diet high in whole grains helped to reduce many of the risk factors associated with HCC, such as inflammation.
Liver Resection Vs TACE For Intermediate Stage Hepatocellular Carcinoma
21 March 2019
According to a study, liver resection may lead to better outcomes than transarterial chemoembolization (TACE) for cirrhotic patients Hepatocellular Carcinoma. The authors of the current study used a Markov model that compared liver resection with TACE over a 15-year period. Data from 31 studies were included in the analysis. Results revealed that patients in the resection group had a mean of 77.8 months expected survival time at 5 years and a survival rate of 47.1%. Those in the TACE group had 48.6 months mean survival and 25.7% survival rate. “Liver resection is superior to TACE regarding the OS of compensated cirrhotic patients with resectable intermediate‐stage HCC. Future large‐scale high‐quality studies are required to stratify patients at this stage for different optimal treatments,” the investigators concluded.
Diabetes Development Linked To Hepatocellular Carcinoma, Mortality In Hepatitis B
20 March 2019
Researchers used study participant data from people with chronic hepatitis B (CHB) without diabetes mellitus (DM), from the Taiwanese National Health Insurance Research Database. It has been shown that for patients with CHB virus, development of DM is an independent risk factor for Hepatocellular Carcinoma (HCC). The study included information on over 2900 patients. At the 11-year follow up, 11.8% of participants developed HCC. Compared with participants without DM, participants with DM had significantly higher risk for HCC development.
Liver Cancer: Discovery Of New Biomarker For Liver Dysfunction Following Partial Hepatectomy
18 March 2019
Liver failure is the most serious complication that can occur following liver resection. The tests available to gage pre-operative risk are expensive and time-consuming. A study done by MedUni Vienna research group has shown that a microRNA signature has the potential to serve as a rapid and reliable predictor. The team, led by Patrick Starlinger from MedUni Vienna’s Department of Surgery and Alice Assinger from MedUni Vienna’s Center for Physiology and Pharmacology, focused on the prediction of postoperative liver dysfunction and clinical outcomes that can be expected following liver resection. MicroRNA signatures are a new approach in this research and are already known as a significant diagnostic tool.
Research Suggests Liver Cells Are More Susceptible To Cancer
18 March 2019
Researchers at the Abramson Cancer Center of the University of Pennsylvania have found that hepatocytes, the chief functional cells of the liver, make the liver more susceptible to cancer cells. The hepatocytes respond to inflammation by activating a protein called STAT3. This then increases the production of other proteins called SAA. These proteins remodel the liver and create the “soil” needed for cancer cells to “seed.” The researchers found that stopping this process by using antibodies that block IL 6, the inflammatory signal that drives this chain reaction, can limit the potential of cancer to spread to the liver. The team, along with researchers from the University of Kentucky showed in their study that therapies targeting hepatocytes may be able to prevent cancer from spreading to the liver.
Reprogramming T Cells To Attack Solid Tumors
18 March 2019
An international team, led by Andrea Pavesi, at A*STAR’s Institute of Molecular and Cell Biology (IMCB), have worked to genetically engineer human T cells to have them specifically attack liver cancer cells in patients with Hepatitis B, and to have the potential for long-term antitumor efficacy. Checkpoint inhibitor therapy uses antibodies to block inhibitory molecules that would otherwise stop T cells from attacking tumors. The receptor protein PD-1is the key to cell exhaustion and a target of checkpoint inhibitor therapy. Adoptive cell therapy involves modifying patient-derived T cells outside the body, to increase their potency, and then injecting them back into the patient.
Daily Aspirin May Reduce HBV-Related Hepatocellular Carcinoma Risk
18 March 2019
A recent study conducted by Lee and colleagues in Taiwan, observed patients on a daily aspirin regimen. Their data showed that patients with hepatitis B virus and were giving aspirin daily, had a 29% lower risk of developing Hepatocellular Carcinoma. Between 1997 and 2012, the researchers recruited and screened 10,615 participants with chronic HBV. Of these patients, 2,123 received daily aspirin for 90 or more consecutive days. At 5 years, patients in the treated group had a significantly lower cumulative incidence of HCC than those in the untreated group. “Daily aspirin therapy may be of help to further improve the chemoprevention of HBV-related Hepatocellular Carcinoma,” Lee and colleagues concluded.
Novel Agents Offer Hope In Hepatocellular Carcinoma
15 March 2019
Sorafenib (Nexavar) has been the only FDA-approved agent available for the first-line treatment of patients with HCC, up until a few years ago. Lenvatinib (Lenvima) has shown to be non-inferior to sorafenib as presented in the findings of the phase III REFLECT trial. Additionally, the FDA review of ramucirumab (Cyramza) is very much anticipated as well. According to Michael A. Morse, MD, FACP, MHS, Cyramza differs from the other drugs on the market in that it is a recombinant monoclonal antibody that binds to VEGFR2, and for which there may be a biomarker. Researchers from the phase III REACH-2 trial have shown improved overall survival (OS) as compared with patients taking the placebo and who had previously been treated with sorafenib.
Results Of Early-Stage Liver Cancer Detection Using Liquid Biopsy Published
13 March 2019
A recent pilot study done by researchers from the National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Genetron Health (Beijing) Co. Ltd (Genetron) focused on early detection of liver cancer in a cohort of HBV carriers at risk for developing HCC. The screening technology, known as HCCscreen, relies on detecting a combination of tumor-specific mutations in cell free DNA (cfDNA) and protein markers. A total of 331 HBV carriers were tested using HCCscreen. The combination of these markers enabled excellent performance of the assessment in a cohort of HBV carriers who had no other symptoms. Using a noninvasive blood test, the liquid biopsy technology can provide important diagnostic indicators HBV carriers. The research team is currently conducting a larger scale clinical trial to further improve and validate the method.
Preclinical Data Shows Combination Immunotherapy Could Stop Liver Cancer Growth
13 March 2019
Researchers from UC San Diego Moores Cancer Center recently reported that combining two reagents effectively stopped the progression of Hepatocellular Carcinoma (HCC). They successfully combined a synthetic double-stranded RNA (dsRNA) polyinosinicpolycytidylic acid (polyIC) with a programmed death-ligand 1 (PD-L1) antibody to achieve this. Feng’s team discovered unexpectedly that polyIC strongly boosts several anti-tumor immune functions in the liver, and that it prevents HCC if administered in the pre-cancer stage. Otherwise, once the tumor is already formed, polyIC has no effect. More research will be done to develop a liver cancer prevention strategy for the large population of patients with chronic liver disease and who at risk for liver cancer development.
Lucence Diagnostics To Develop AI Tools For Liver Cancer Treatment
12 March 2019
Lucence Diagnostics has recently announced their new project to develop AI algorithms for improving diagnosis and treatment of liver cancer. Lucence Diagnostics is a genomic medicine company with hopes for a world without avoidable cancer deaths. They specialize in non-invasive blood tests that improve cancer detection and treatment selection. Researchers, led by Olivier Gevaert, PhD, Assistant Professor of Medicine and of Biomedical Data Science at the Stanford University School of Medicine, will use tumor imaging and molecular data of liver cancer patients to help doctors make better treatment decisions. This study will evaluate over 5,000 patients.
Computer Neural Network Shows Potential For Liver Cancer Diagnosis
6 March 2019
Researchers from Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, the Second Hospital of Suzhou University and other research institutions have developed the neural network for HCC grading. They achieved this by combining two classic neural networks and training the network with enhanced nuclear magnetic resonance images using 75 patients. The grading of HCC is very important in the clinical diagnoses, treatments and prognoses of the disease. Their proposed model achieved an accuracy of 83% in classifying HCC. Researchers plan to use the model for liver cancer diagnosis and treatment system, which will help doctors make better surgery plans for liver cancer patients.
Eating Tomatoes To Fight Liver Cancer
1 March 2019
A recent study using mouse models found that the lycopene in tomatoes reduced fatty liver disease, inflammation, and liver cancer development caused by high-fat diets. Xiang-Dong Wang, a senior scientist and associate director of the Jean Mayer USDA Human Research Center on Aging at Tufts, is conducting several studies to see how food can help prevent cancer development. One of the foods of interest is tomatoes, which are rich in lycopene, a naturally occurring pigment that gives many fruits and vegetables their reddish hue. Researchers evaluated how well tomato powder protected mice against inflammation and cancer, that were originally infected with a liver carcinogen and then fed an unhealthy high-fat diet.
For past liver cancer news, please visit our Liver Cancer News Archives.